ProADM and/or histones as markers indicating an adverse event
US11041867B2 · kind B2 · utility
0Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 1, 2018 |
| Grant date | Jun 22, 2021 |
| Priority date | — |
| Expiry date | Feb 1, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/56
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to diagnosis, prognosis, risk assessment, and/or risk stratification of an adverse event, particularly mortality, of a subject. The invention relates to a method that comprises determining a level of proadrenomedullin (proADM) in a sample of said subject, and wherein said level of proADM is indicative of said adverse event of said subject, wherein said level of proADM is compared to a reference level of proADM; and wherein said adverse event of said subject is identified based on the comparison. The invention further relates to kits for carrying out the methods of the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.